{"id":4353,"date":"2010-11-03T19:20:24","date_gmt":"2010-11-03T23:20:24","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=4353"},"modified":"2011-07-19T17:44:44","modified_gmt":"2011-07-19T21:44:44","slug":"paricalcitol-reduces-albuminuria-in-diabetic-nephropathy","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/11\/03\/paricalcitol-reduces-albuminuria-in-diabetic-nephropathy\/","title":{"rendered":"Paricalcitol Reduces Albuminuria in Diabetic Nephropathy"},"content":{"rendered":"<p>Selective vitamin D receptor activation with paricalcitol may help prevent progression of renal failure in patients with diabetic nephropathy who are already taking renin-angiotensin-aldosterone system (RAAS) inhibitors, according to <a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2810%2961032-X\/abstract\">a new study published online in the <em>Lancet<\/em><\/a>.\u00a0In the VITAL study, U.S. and European investigators randomized 281 patients with type 2 diabetes and albuminuria who were already receiving RAAS inhibitors to placebo or to one of two doses of paricalcitol.<\/p>\n<p>After 24 weeks, the urinary albumin-to-creatine ratio (UACR) declined by 20% and 24-hour urinary albumin excretion fell by 28% in patients receiving the higher dose of paricalcitol. No difference in adverse events across the groups was observed. The investigators concluded that paricalcitol might &#8220;be an important adjunctive treatment, providing optimum management of renal osteodystrophy, with little hypercalcaemia, and lowering residual albuminuria.&#8221;<\/p>\n<p><a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2810%2961304-9\/fulltext\">In an accompanying editorial<\/a>, Merlin Thomas and Mark Cooper call for &#8220;long-term and larger clinical trials&#8221; to test whether paricalcitol or similar drugs &#8220;can ultimately improve mortality and cardiovascular outcomes.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selective vitamin D receptor activation with paricalcitol may help prevent progression of renal failure in patients with diabetic nephropathy who are already taking renin-angiotensin-aldosterone system (RAAS) inhibitors, according to a new study published online in the Lancet.\u00a0In the VITAL study, U.S. and European investigators randomized 281 patients with type 2 diabetes and albuminuria who were [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[525,524,523,526],"class_list":["post-4353","post","type-post","status-publish","format-standard","hentry","category-general","tag-albuminuria","tag-diabetic-nephropathy","tag-paricalcitol","tag-vital-study"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=4353"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4353\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=4353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=4353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=4353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}